2024.06.25
On June 18, 2024, Grifols, S.A. ("Grifols"), a global healthcare company and a leading producer of plasma-derived medicines, announced completion of the sale of a 20% equity stake in Shanghai RAAS (“SRAAS”) to Haier Group Corporation (“Haier Group”) for RMB 12.5 billion (approximately USD 1.8 billion). Grifols retains a 6.58% equity stake in SRAAS while forging a strategic alliance with Haier Group and SRAAS. For more information please visit: Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
JunHe and Osborne Clarke Spain together served as legal counsel for Grifols in this transaction. In 2019, the two firms advised Grifols on its acquisition of a 26.2% stake in SRAAS by contributing its non-majority share in its US subsidiary Grifols Diagnostic Solutions Inc. That transaction was recognized as the Deal of the Year 2020 by China Business Law Journal.
On the JunHe side, the transaction was led by partners CHEN, Jiang (Joe) and YAO, Yunke and assisted by TAO, Xudong, Janet Hui, XIANG, Fangfang (Lori) and DONG, Zhe. On the Osborne Clarke Spain side, the transaction was led by partners Tomás Dagá, Oscar Calsamiglia and José Ramón Medina and assisted by Laura de la Cruz, María Montehermoso and Marian Aleu.
